Mucosal Leishmaniasis Clinical Trial
Official title:
Treatment of Bolivian Mucosal Leishmaniasis With Miltefosine, Pentavalent Antimony or Liposomal Amphotericin B
The purpose of this protocol is to conduct a randomized comparison of the efficacy and tolerance of miltefosine, LAMB, and pentavalent antimony for the treatment of mucosal leishmaniasis. With such controlled pharmacodynamic data, and additional considerations of administrative convenience (oral >>IV) and cost, we hope that it will be possible for policy makers, treatment professionals, and patients to choose the most appropriate therapy for ML.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT01301937 -
Low Antimonial Dosage in American Mucosal Leishmaniasis
|
Phase 2/Phase 3 | |
| Completed |
NCT01050907 -
Miltefosine to Treat Mucocutaneous Leishmaniasis
|
Phase 2 |